Ryan J. Sullivan
Experienced in Heart Failure

Dr. Ryan J. Sullivan

Internal Medicine
Critical Care Pulmonary And Sleep Associates Professional Llp
274 Union Blvd, Suite 200, 
Lakewood, CO 
9 Years of Experience
Experienced in Heart Failure
Critical Care Pulmonary And Sleep Associates Professional Llp
274 Union Blvd, Suite 200, 
Lakewood, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ryan Sullivan is a primary care provider, practicing in Internal Medicine in Lakewood, Colorado. Dr. Sullivan has been practicing medicine for over 9 years and is rated as an Experienced provider by MediFind in the treatment of Heart Failure. His top areas of expertise are Metastatic Uveal Melanoma, Myocarditis, Melanoma of the Eye, Colonoscopy, and Thyroidectomy.

His clinical research consists of co-authoring 374 peer reviewed articles and participating in 28 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Heart Failure.

Graduate Year
2016
Specialties
Internal Medicine
Hospital Affiliations
Centura Health-St Anthony North Health Campus
Littleton Adventist Hospital, Centura Health
St Anthony Summit Medical Center
Centura Health-St Anthony Hospital
Centura Health-Avista Adventist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CRITICAL CARE PULMONARY AND SLEEP ASSOCIATES PROFESSIONAL LLP
274 Union Blvd, Suite 200, Lakewood, CO 80228

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Dabrafenib, Trametinib, Spartalizumab (PDR001)
Study Phase: Phase 3
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Enrollment Status: Suspended
Publish Date: September 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Other, Drug
Study Drugs: Dabrafenib, Navitoclax, Trametinib
Study Phase: Phase 1/Phase 2
A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Dabrafenib, Trametinib
Study Phase: Phase 2
First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy
First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy
Enrollment Status: Completed
Publish Date: August 22, 2025
Intervention Type: Drug
Study Drug: Single Arm
Study Phase: Phase 1
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Tocilizumab
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Enrollment Status: Terminated
Publish Date: October 16, 2024
Intervention Type: Other, Drug
Study Drugs: Dabrafenib, Onalespib, Trametinib
Study Phase: Phase 1
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Enrollment Status: Completed
Publish Date: September 04, 2024
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: BVD-523
Study Phase: Phase 2
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)
An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Biological
Study Phase: Phase 1
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Genetic
Study Phase: Phase 1
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: September 03, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Enrollment Status: Terminated
Publish Date: February 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 25 Less Clinical Trials

374 Total Publications

Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Journal: Journal for immunotherapy of cancer
Published: August 27, 2025
Similar Doctors
Distinguished in Heart Failure
Dr. David B. Bekelman
Internal Medicine
Distinguished in Heart Failure
Dr. David B. Bekelman
Internal Medicine
12605 E 16th Ave, 
Aurora, CO 
 (15.5 miles away)
720-848-0000
Languages Spoken:
English

David Bekelman is a primary care provider, practicing in Internal Medicine in Aurora, Colorado. Dr. Bekelman is rated as an Advanced provider by MediFind in the treatment of Heart Failure. His top areas of expertise are Heart Failure, Chronic Obstructive Pulmonary Disease (COPD), Subcutaneous Emphysema, and Alpha-1 Antitrypsin Deficiency (AATD).

Distinguished in Heart Failure
Dr. Mark F. Berntsen
Internal Medicine
Distinguished in Heart Failure
Dr. Mark F. Berntsen
Internal Medicine

Poudre Valley Medical Group LLC

6767 29th St, 
Greeley, CO 
 (49.7 miles away)
970-224-3636
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Berntsen is a primary care provider, practicing in Internal Medicine in Greeley, Colorado. Dr. Berntsen is rated as a Distinguished provider by MediFind in the treatment of Heart Failure. His top areas of expertise are Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, and Heart Failure. Dr. Berntsen is currently accepting new patients.

Advanced in Heart Failure
Dr. Daniel R. Zenk
Internal Medicine
Advanced in Heart Failure
Dr. Daniel R. Zenk
Internal Medicine

Poudre Valley Medical Group LLC

4404 Barranca Ln, Unit 101, 
Castle Rock, CO 
 (26.2 miles away)
720-733-5260
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Zenk is a primary care provider, practicing in Internal Medicine in Castle Rock, Colorado. Dr. Zenk is rated as a Distinguished provider by MediFind in the treatment of Heart Failure. His top areas of expertise are Familial Hypertension, Hypertension, Glucocorticoid-Remediable Aldosteronism, and Familial Combined Hyperlipidemia. Dr. Zenk is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sullivan's expertise for a condition
ConditionClose
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile